Teacher Retirement System of Texas Purchases 6,209 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Teacher Retirement System of Texas boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 20.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,797 shares of the company’s stock after purchasing an additional 6,209 shares during the period. Teacher Retirement System of Texas’ holdings in Sana Biotechnology were worth $60,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of SANA. FMR LLC lifted its position in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after buying an additional 4,438,949 shares during the last quarter. State Street Corp lifted its holdings in shares of Sana Biotechnology by 4.2% in the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock valued at $13,175,000 after purchasing an additional 276,055 shares in the last quarter. Corient Private Wealth LLC grew its holdings in shares of Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after purchasing an additional 730,699 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock worth $1,722,000 after purchasing an additional 8,666 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Insider Activity at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 31.10% of the stock is currently owned by company insiders.

Sana Biotechnology Stock Up 8.7 %

NASDAQ SANA opened at $1.63 on Thursday. The company has a market capitalization of $366.79 million, a price-to-earnings ratio of -1.16 and a beta of 1.63. Sana Biotechnology, Inc. has a twelve month low of $1.48 and a twelve month high of $10.50. The stock has a fifty day simple moving average of $2.71 and a 200 day simple moving average of $2.97.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Sana Biotechnology in a research report on Tuesday, March 18th. Jefferies Financial Group assumed coverage on Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 price objective on the stock. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a report on Tuesday, March 18th. Finally, TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.